Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment
Background and aims: Severe asthma may require the prescription of one of the biologic drugs currently available, using surrogate markers of airway inflammation (serum IgE levels and allergic sensitization for anti-IgE, or blood eosinophils for anti-IL5/IL5R). Our objective: to assess upper and lowe...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-11-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/1753466620965151 |
| _version_ | 1818948342382592000 |
|---|---|
| author | Manuela Latorre Elena Bacci Veronica Seccia Maria Laura Bartoli Cristina Cardini Silvana Cianchetti Ludovica Cristofani Antonella Di Franco Mario Miccoli Ilaria Puxeddu Alessandro Celi Pierluigi Paggiaro |
| author_facet | Manuela Latorre Elena Bacci Veronica Seccia Maria Laura Bartoli Cristina Cardini Silvana Cianchetti Ludovica Cristofani Antonella Di Franco Mario Miccoli Ilaria Puxeddu Alessandro Celi Pierluigi Paggiaro |
| author_sort | Manuela Latorre |
| collection | DOAJ |
| description | Background and aims: Severe asthma may require the prescription of one of the biologic drugs currently available, using surrogate markers of airway inflammation (serum IgE levels and allergic sensitization for anti-IgE, or blood eosinophils for anti-IL5/IL5R). Our objective: to assess upper and lower airway inflammation in severe asthmatics divided according to the eligibility criteria for one of the target biologic treatments. Methods: We selected 91 severe asthmatics, uncontrolled despite high-dose ICS-LABA, and followed for >6 months with optimization of asthma treatment. Patients underwent clinical, functional and biological assessment, including induced sputum and nasal cytology. They were then clustered according to the eligibility criteria for omalizumab or mepolizumab/benralizumab. Results: Four clusters were selected: A (eligible for omalizumab, n = 23), AB (both omalizumab and mepolizumab, n = 26), B (mepolizumab, n = 22) and C (non-eligible for both omalizumab and mepolizumab, n = 20). There was no difference among clusters for asthma control (Asthma Control Test and Asthma Control Questionnaire 7), pre-bronchodilator forced expiratory volume in 1 s, serum IgE and fractional exhaled nitric oxide levels. Sputum eosinophils were numerically higher in clusters AB and B, in agreement with the higher levels of blood eosinophils. Allergic rhinitis was more frequent in clusters A and AB, while chronic rhinosinusitis with nasal polyps prevalence increased progressively from A to C. Eosinophils in nasal cytology were higher in clusters AB, B and C. Conclusion: Eosinophilic upper and lower airway inflammation is present in the large majority of severe asthmatics, independently from the prescription criteria for the currently available biologics, and might suggest the use of anti-IL5/IL5R or anti IL4/13 also in patients without blood eosinophilia. The reviews of this paper are available via the supplemental material section . |
| first_indexed | 2024-12-20T08:45:16Z |
| format | Article |
| id | doaj.art-f7a9d0f0dde945dcaa6bb380050856c3 |
| institution | Directory Open Access Journal |
| issn | 1753-4666 |
| language | English |
| last_indexed | 2024-12-20T08:45:16Z |
| publishDate | 2020-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Respiratory Disease |
| spelling | doaj.art-f7a9d0f0dde945dcaa6bb380050856c32022-12-21T19:46:16ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662020-11-011410.1177/1753466620965151Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatmentManuela LatorreElena BacciVeronica SecciaMaria Laura BartoliCristina CardiniSilvana CianchettiLudovica CristofaniAntonella Di FrancoMario MiccoliIlaria PuxedduAlessandro CeliPierluigi PaggiaroBackground and aims: Severe asthma may require the prescription of one of the biologic drugs currently available, using surrogate markers of airway inflammation (serum IgE levels and allergic sensitization for anti-IgE, or blood eosinophils for anti-IL5/IL5R). Our objective: to assess upper and lower airway inflammation in severe asthmatics divided according to the eligibility criteria for one of the target biologic treatments. Methods: We selected 91 severe asthmatics, uncontrolled despite high-dose ICS-LABA, and followed for >6 months with optimization of asthma treatment. Patients underwent clinical, functional and biological assessment, including induced sputum and nasal cytology. They were then clustered according to the eligibility criteria for omalizumab or mepolizumab/benralizumab. Results: Four clusters were selected: A (eligible for omalizumab, n = 23), AB (both omalizumab and mepolizumab, n = 26), B (mepolizumab, n = 22) and C (non-eligible for both omalizumab and mepolizumab, n = 20). There was no difference among clusters for asthma control (Asthma Control Test and Asthma Control Questionnaire 7), pre-bronchodilator forced expiratory volume in 1 s, serum IgE and fractional exhaled nitric oxide levels. Sputum eosinophils were numerically higher in clusters AB and B, in agreement with the higher levels of blood eosinophils. Allergic rhinitis was more frequent in clusters A and AB, while chronic rhinosinusitis with nasal polyps prevalence increased progressively from A to C. Eosinophils in nasal cytology were higher in clusters AB, B and C. Conclusion: Eosinophilic upper and lower airway inflammation is present in the large majority of severe asthmatics, independently from the prescription criteria for the currently available biologics, and might suggest the use of anti-IL5/IL5R or anti IL4/13 also in patients without blood eosinophilia. The reviews of this paper are available via the supplemental material section .https://doi.org/10.1177/1753466620965151 |
| spellingShingle | Manuela Latorre Elena Bacci Veronica Seccia Maria Laura Bartoli Cristina Cardini Silvana Cianchetti Ludovica Cristofani Antonella Di Franco Mario Miccoli Ilaria Puxeddu Alessandro Celi Pierluigi Paggiaro Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment Therapeutic Advances in Respiratory Disease |
| title | Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment |
| title_full | Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment |
| title_fullStr | Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment |
| title_full_unstemmed | Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment |
| title_short | Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment |
| title_sort | upper and lower airway inflammation in severe asthmatics a guide for a precision biologic treatment |
| url | https://doi.org/10.1177/1753466620965151 |
| work_keys_str_mv | AT manuelalatorre upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT elenabacci upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT veronicaseccia upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT marialaurabartoli upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT cristinacardini upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT silvanacianchetti upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT ludovicacristofani upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT antonelladifranco upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT mariomiccoli upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT ilariapuxeddu upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT alessandroceli upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment AT pierluigipaggiaro upperandlowerairwayinflammationinsevereasthmaticsaguideforaprecisionbiologictreatment |